CD19 and neoplasm: Progression of intravenously injected Raji.CD33.ff/luc xenograft tumor burden was monitored following administration of CD19 CAR, SC-DARIC33 (tested at 2 doses), and CD19-specific DARIC T cell products manufactured using a GMP process (see Figure 5C for schema).